EMEA-000371-PIP04-16

Key facts

Invented name
Revlimid
Active substance
lenalidomide
Therapeutic area
Oncology
Decision number
EMEA-000371-PIP04-16
PIP number
EMEA-000371-PIP04-16
Pharmaceutical form(s)
  • Capsule
  • hard
Condition(s) / indication(s)
Treatment of mature B-cell neoplasms
Route(s) of administration
Oral use
Contact for public enquiries
Celgene Europe Limited
Tel. +41 327298500
E-mail: medinfo.intl@celgene.com
Decision type
W: decision granting a waiver in all age groups for all conditions/indications

Decision

How useful was this page?

Add your rating